Preparation and evaluation of nano-hydroxyapatite/poly(styrene-divinylbenzene) porous microsphere for aspirin carrier

被引:0
作者
Sen Li
Kuan Wang
Kue-Chieh Alan Chang
Ming Zong
Jing Wang
YongGang Cao
YuHua Bai
TaiMing Wei
ZhiRen Zhang
机构
[1] Harbin Medical University,School of Pharmacy, Daqing Campus
[2] Dalian University of Technology,School of Life Science and Biotechnology
[3] Harbin Medical University,Departments of Pharmacy and Cardiology, The 2nd Affiliated Hospital of Harbin Medical University, Key Laboratories of Ministry of Education for Myocardial Ischemia Mechanism and Treatment
来源
Science China Chemistry | 2012年 / 55卷
关键词
porous; nano-hydroxyapatite; microsphere; carrier; aspirin;
D O I
暂无
中图分类号
学科分类号
摘要
A novel vehicle for the delivery of aspirin (ASA) was prepared from porous nano-hydroxyapatite/poly(styrene-divinylbenzene) [nano-HAP/P(St-DVB)] composite microspheres by grafting nano-HAP [Ca10(PO4)6(OH)2] onto porous P(St-DVB) microspheres. Four types of porous composite microspheres were prepared, each with different nano-HAP contents. The ASA-loaded composite microspheres prepared with 10% and 15% nano-HAP (mass ratio) exhibited excellent buoyancy with relatively short instantaneous floating time (within 10 min) and a long sustained floating time (12 h) in simulated gastric juice. They also offered good sustained release of ASA (up to 8 h). Furthermore, these composite microspheres displayed good buffering capacity that prevented the buildup of acidity caused by hydrolysis of ASA, keeping the pH of gastric juice within the normal range (pH 0.9 to 1.5). The results showed that porous nano-HAP/P(St-DVB) composite microspheres prepared with 10% and 15% nano-HAP could be used as a novel drug carrier for ASA, providing a sustained release dose without leading to stomach irritation, a side effect that is often associated with ASA medication.
引用
收藏
页码:1134 / 1139
页数:5
相关论文
共 65 条
[1]  
Yusuf S.(2001)Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 494-505
[2]  
Zhaoa F.(1988)Aspirin, heparin, or both, to treat acute unstable angina N Engl J Med 319 1105-1111
[3]  
Mehta S.R.(2010)Impact of upper gastrointestinal lesions in patients on low-dose aspirin therapy: Preliminary study J Gastroenterol Hepatol 25 23-30
[4]  
Theroux P.(1999)Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N Engl J Med 340 1888-1899
[5]  
Ouimet H.(2004)Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial Gastroenterology 127 395-402
[6]  
McCans J.(2007)Semimicro column high-performance liquid chromatography with UV detection for quantification of aspirin and salicylic acid and its application to patients’s sera administered with low-dose enteric-coated aspirin Biomed Chromatogr 21 221-224
[7]  
Kawai T.(1996)Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product Lancet 348 1413-1416
[8]  
Watanabe M.(2009)Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease Clin Gastroenterol 43 130-132
[9]  
Yamashina A.(2010)Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma J Pharm Pharm Sci 13 1-10
[10]  
Wolfe M.M.(2008)Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome Am J Gastro 103 865-871